Related Experiment Video

Updated: Jun 6, 2025

Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library
07:32

Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library

Published on: September 30, 2019

7.6K

Pharmacological and Biological Targeting of FGFR1 in Cancer

Shuai Fan1, Yuxin Chen1, Wenyu Wang1

  • 1State Key Laboratory of Molecular Medicine and Biological Diagnosis and Treatment (Ministry of Industry and Information Technology), School of Life Science, Beijing Institute of Technology, Beijing 100081, China.

Current Issues in Molecular Biology
|November 26, 2024
PubMed

Insights

Fibroblast growth factor receptor 1 (FGFR1) alterations drive cancer by activating key cell signaling pathways. This review details FGFR1 aberrations and current targeted therapies for improved cancer treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cellular Signaling

Background:

  • Fibroblast growth factor receptor 1 (FGFR1) is crucial for cell proliferation, differentiation, and survival.
  • FGFR1 signaling pathways, including RAS-MAPK and PI3K-AKT, are vital for normal cellular functions.
  • Aberrant FGFR1 signaling drives oncogenesis through uncontrolled cell division and metastasis.

Purpose of the Study:

  • To review FGFR1 activation mechanisms and signaling pathways.
  • To detail the types of FGFR1 aberrations in cancer.
  • To provide an overview of current therapies targeting FGFR1 alterations.

Main Methods:

  • Literature review of FGFR1 activation, signaling, and aberrations.
  • Compilation of current therapeutic strategies targeting FGFR1.

Main Results:

  • FGFR1 alterations lead to constitutive pathway activation, promoting cancer.
  • Various FGFR1 aberrations contribute to oncogenesis.
  • Targeted therapies are emerging for specific FGFR1 alterations.

Conclusions:

  • Understanding FGFR1 aberrations is key to developing effective cancer treatments.
  • Targeting specific FGFR1 alterations offers new therapeutic perspectives.
  • Further research into FGFR1-targeted drugs can improve patient outcomes.
Keywords:
FGFR1TKIaberrationantibody drugsligand trapstargeted therapeutics

More Related Videos

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells09:37

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells

Published on: August 25, 2021

1.7K
Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures07:48

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Published on: December 26, 2016

11.3K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.7K
Transducer Mechanism: G Protein–Coupled Receptors01:30

Transducer Mechanism: G Protein–Coupled Receptors

G Protein–Coupled Receptors (GPCRs) are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to various stimuli. GPCRs regulate critical physiological pathways and are excellent drug targets for treating diseases such as diabetes, cancer, obesity, depression, or Alzheimer's. Nearly 35% of approved drugs implement their therapeutic effects by selectively interacting with specific GPCRs.
GPCRs are also called heptahelical,...
1.8K